Erste Group Upgrades Novartis (NVS) to Buy, 'currently valued below the sector average despite the good growth prospects'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Voyager Therapeutics (VYGR) Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
September 5, 2024 8:09 AM EDTVoyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyagers TRACER capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally... More
Goldman Sachs Downgrades Novartis (NVS) to Neutral
September 5, 2024 2:43 AM EDTGoldman Sachs analyst James Quigley downgraded Novartis (NYSE: NVS) from Buy to Neutral with a price target of $121.00 (from $119.00).
The analyst comments: "We downgrade our rating on Novartis from Buy to Neutral, driven by solid recent share price performance, earnings upgrades... More
Goldman Sachs Downgrades Novartis (NOVN:SW) (NVS) to Neutral
September 5, 2024 2:42 AM EDTGoldman Sachs analyst James Quigley downgraded Novartis (NOVN:SW) (NYSE: NVS) from Buy to Neutral with a price target of CHF103.00 (from CHF105.00).
The analyst comments: "We downgrade our rating on Novartis from Buy to Neutral, driven by solid recent share price... More
